Laser hair removal — detailed notes
Date compiled: 2026-04-18. Confidence tiers: C1 = Phase 3 / multiple meta-analyses; C2 = multiple RCTs; C3 = small RCT / strong open-label; C4 = case series / anecdote; C5 = hype.
1. Mechanism (C1)
- Selective photothermolysis (SPTL) — Anderson & Parrish, Science 220:524-527 (1983). Pulsed light + melanin-selective absorption + pulse shorter than target's thermal relaxation time (TRT) → confined thermal damage. Foundation for all modern LHR. PMID 6836297.
- Chromophore = melanin (eumelanin ≫ pheomelanin) in hair shaft and matrix. Pheomelanin (red/blonde) and grey/white (near-zero melanin) fail — no absorption target.
- Target = bulge stem cells and dermal papilla. Heat conducts from the pigmented shaft to these follicle-stem regions. Bulge cells can survive sub-lethal exposures, which is why the result is "permanent reduction," not full eradication (Sun 2022, PMID 35289409).
- Thermal relaxation time: coarse terminal hair ~40-100 ms; epidermis 3-10 ms. Pulse durations are typically tuned between these windows, with cooling to protect the epidermis.
- Thermal damage time (TDT) concept — Altshuler & Anderson 2001 (PMID 12030874) — longer pulses (170-1000 ms) allow heat to diffuse from shaft to bulge, enabling destruction of stem cells even when direct absorption drops off.
- FDA nomenclature: lasers clear for "permanent hair reduction". Electrolysis is the only device type cleared for "permanent hair removal".
2. Wavelengths and machines
Ruby 694 nm (C2, obsolete)
Strong epidermal-melanin absorption → hypopigmentation risk even at Fitzpatrick II. Essentially retired from commercial practice. Campos 2000 was the main long-term efficacy source.
Alexandrite 755 nm (C1)
- Best for Fitzpatrick I-III. Strong melanin affinity with shallow-to-moderate penetration. Typical fluence 20-50 J/cm², pulse 2-20 ms, 10-18 mm spot, DCD cryogen cooling.
- Lloyd/Eremia 2001 long-term series: 73-79% reduction across Fitz I-III (PMID 11737124). Williams 2023 network meta-analysis showed no single class clearly superior.
- Caveat: worst wavelength for paradoxical hypertrichosis on face/neck (see §6) and for darker skin — risk of epidermal burns / dyspigmentation in Fitz IV-VI.
Diode 800-810 nm (C1)
- Versatile across Fitz I-IV, deeper penetration than alexandrite. Typical 10-40 J/cm², pulse 5-400 ms (SHR mode pushes 400+).
- Representative machines: Lumenis LightSheer DESIRE (805 nm, HS vacuum-assist + XC contact cooling); Candela GentleLASE Pro (808 nm variant).
- 940-980 nm diode variants exist with marginal extra depth, limited independent head-to-head evidence.
Nd:YAG 1064 nm (C1)
- Safest for Fitzpatrick V-VI. Longest wavelength = deepest penetration, lowest epidermal melanin absorption. Alster 2001/2003 and later demonstrated 80-90% density reduction with minimal AE in dark skin. PIH rate ~2-3% with Nd:YAG vs up to 19% with shorter wavelengths in skin of color.
- Meta-analytic long-term reduction (Husain 2022, PMID 35634805): Nd:YAG 30-73.6%; alexandrite 35-84.2%; diode 32.5-69.2%.
- Trade-off: less efficient on light/fine hair than alexandrite; more sessions needed for a given density.
Long-pulse vs SHR / "in-motion" (C2)
- Long-pulse: single high-fluence pulses at TRT.
- SHR (super-hair-removal): low-fluence (~5-10 J/cm²) + high rep rate (~10 Hz) + continuous sweeping motion, cumulative heating. Lower pain, lower paradoxical-induction risk, safer for tanned skin. Alma Soprano codified this.
Tri-wavelength "stacked" diode (C3)
- Alma Soprano Titanium / ICE: 755 + 810 + 1064 nm simultaneously, marketed for all Fitz types. Mechanistically plausible but independent head-to-head evidence thin.
DEKA Motus AX / AY with Moveo (C3)
- Alexandrite (AX) or Alex+Nd:YAG (AY) via 20 mm sapphire tip in Moveo gradual-motion technique. Low peak fluence, cumulative heating. Marketed safe to Fitz VI but literature is mostly manufacturer-sponsored.
Candela GentleMax Pro (C1)
- 755 alex + 1064 Nd:YAG in one platform with DCD cryogen cooling. Widely used reference device.
Erbium glass 1540/1550 and picosecond lasers
- Not used for hair removal. 1540 is studied for growing scalp hair in AGA. Picosecond lasers target tattoo ink / pigmentation.
3. Fitzpatrick × wavelength matrix (C1)
| Fitzpatrick | Preferred | Alternative | Avoid |
|---|---|---|---|
| I-II | Alexandrite 755 | Diode 810 | — |
| III | Alexandrite, Diode | Nd:YAG, SHR | — |
| IV | Diode SHR, Nd:YAG | Alex cautious | High-fluence alex |
| V | Nd:YAG 1064 | Diode SHR, tri-wavelength SHR | Alex, ruby |
| VI | Nd:YAG 1064 | SHR diode low fluence | Alex, ruby, high-fluence diode |
- Ideal patient = dark terminal hair on light untanned skin. Maximises follicle-epidermis melanin contrast.
- Fails on: blonde, red (pheomelanin absorbs weakly), grey, white (no melanin). Meta-analyses confirm these colours are reliably addressed only by electrolysis. Liposomal-melanin augmentation (Lipoxôme) trials disappointing (~14% reduction at 6 mo).
4. Protocol (C1)
- Sessions: 6-12 typical; many patients need 8-12+.
- Intervals: face / hormonally-active 4-6 weeks; trunk / limbs 6-10; legs 8-12.
- Rationale: only anagen follicles are laser-susceptible (intact shaft + peak melanin). ~10-20% of follicles in anagen at any moment; interval allows telogen→anagen cycling.
- Expected clearance: 70-90% terminal hair reduction after full course. Not eradication. Touch-ups q 6-24 months common.
- Meta-analytic pattern: leg hair shows greatest long-term reduction; facial hair least, because facial follicles are hormone-sensitive and new terminal hairs recruit continuously from vellus pool.
5. Outcomes evidence
- Husain 2022 systematic review (PMID 35634805): long-term reduction Nd:YAG 30-73.6%, alex 35-84.2%, diode 32.5-69.2%.
- Williams 2023 network meta-analysis, 13 RCTs, n=652 (PMID 37493187): diode significantly > control at 3 and 6 mo; no class superiority.
- Haedersdal 2006 Cochrane (11 RCTs, n=444, low quality): ~50% reduction at 6 mo with alex/diode; weaker evidence for Nd:YAG at the time, since strengthened.
- Haedersdal 2006 evidence review: 3-session post-6-mo reductions — diode 57.5%, alex 54.7%, ruby 52.8%, Nd:YAG 42.3%.
- Dorgham 2020 skin-of-color meta-analysis (PMID 31587390): alex > IPL; diode ≈ Nd:YAG ≈ IPL; Nd:YAG favored over IPL for PIH avoidance.
- Duration beyond 12 mo sparsely studied; regrowing hair typically finer/lighter (partial miniaturization).
6. Side effects and complications (C1)
- Common/transient: erythema, perifollicular edema (actually a desirable endpoint), pruritus. Resolve <7 days. Erythema rate ~58% across ≥6-session courses.
- Burns / blistering: rare with appropriate wavelength; higher in Fitz IV-VI if wavelength/fluence wrong or skin tanned.
- Post-inflammatory hyperpigmentation: up to 19% with short-wavelength lasers in dark skin; ~2-3% with Nd:YAG. One Black-skin cohort: 28%.
- Hypopigmentation: more common with ruby, alex on darker skin; often permanent.
- Scarring: rare; increased if burns occur or patient is keloid-prone.
- Ocular injury — iris atrophy (65% of injury cases), uveitis (60%), posterior synechiae, pupillary distortion, cataract, retinal hemorrhage (Nd:YAG). Periocular treatments highest risk. Lerner 2017: 34/40 injured patients wore no eyewear; 5 wore non-wavelength-specific goggles. Wavelength-specific goggles mandatory for patient and operator. PMC5843357.
- Mole changes: treated nevi can fade or change dermatoscopic features; baseline dermoscopy advised. No reported melanoma induction in 30+ years.
- General review: Lanigan 2006 (PMID 16816888).
Paradoxical hypertrichosis (C2)
- Incidence: 0.6-10% cited; 2024 prospective study found 0.34% but alex-dominated; 2025 series showed ~3-5% on face.
- Proposed mechanism: subthermal / subthreshold fluence stimulating dormant (telogen) follicles + cycle synchronization + inflammatory vellus→terminal conversion. Unconfirmed.
- Risk factors: alexandrite and IPL most implicated; Fitz III-IV with Mediterranean / Middle Eastern / South Asian ancestry; female face/neck (especially jawline); underlying PCOS or hyperandrogenism. Some 2025 data show higher incidence in men — interpret cautiously (Moriguchi 2025 PMC12040530).
- Management: switch to Nd:YAG 1064 or SHR diode; raise fluence to avoid sub-threshold; treat affected area at full protocol to destroy induced hairs; electrolysis for residuals; investigate endocrinopathy.
7. Pre- and post-care (C2)
- Pre (4+ weeks): no plucking, waxing, threading, or epilating (removes chromophore). Shaving OK and required day-of.
- Day-of: shave 12-24 h prior; clean skin, no lotions/deodorants.
- Sun / self-tanner: avoid 4-6 weeks pre, 2-4 weeks post. Tanned epidermis competes for absorption.
- Retinoids: discontinue 3-7 days pre and post.
- Isotretinoin: ASDS 2017 consensus (Waldman, PMID 28498204) — 6-month wait is NOT evidence-based for non-ablative LHR. 1485 procedures reviewed, no signal of harm. Many clinics still impose the old rule conservatively.
- Topical anaesthetic (see anesthetic table below): EMLA, LMX-4, tetracaine, BLT compounded, Pliaglis. Lidocaine systemic toxicity is a real risk with large-surface-area laser prep; cap total cream area / dose.
- Cooling during treatment: sapphire/copper contact, cryogen spray (Candela DCD), forced cold air (Zimmer Cryo 6). Essential at higher fluences.
- Post: cool compresses, bland emollient, topical steroid if inflammatory response, mineral SPF 30+, avoid heat 24-48 h.
Contraindications / red flags
- Active skin cancer / melanoma in field.
- Recent UV exposure / self-tanner.
- Active HSV — defer; prophylactic valacyclovir 500 mg BID for perioral/genital HSV-positive patients.
- Tattoos in field — risk of ink fragmentation, burns.
- Chrysotherapy (gold therapy) history — avoid Nd:YAG (chrysiasis risk).
- Photosensitising drugs (tetracyclines, fluoroquinolones, amiodarone, thiazides, retinoids) — variably implicated; practice varies.
- Pregnancy — no demonstrated harm, conventionally deferred as precaution.
- Keloid tendency — test spot first.
- Vitiligo, psoriasis, active eczema in field — Koebner risk.
8. Laser for PFB (C2)
- Long-pulse Nd:YAG 1064 nm = first-line laser for PFB in Fitz IV-VI beards.
- Ross 2002 JAAD: 2-session Nd:YAG significantly reduced papule counts in Fitz IV-VI.
- Smith 2009 JDDS (n=26, Fitz IV-VI): post-treatment 11.6 vs 30.1 papules untreated.
- Battle 2021 (US service members, 74% Black): 88% satisfied, 70% ≥75% lesion reduction, 96% could shave again; PFB recurrence common (84% over time) — maintenance needed.
- Adjunct: eflornithine + Nd:YAG > Nd:YAG alone (Aboelsaad 2021 PMID 33629488).
- Insurance: often covered for PFB when documented medical (not cosmetic), especially in Black patients; US military historically covered for uniform/grooming waivers.
9. Transgender hair removal (C2)
- Facial and neck: 8-12+ laser sessions typical + electrolysis for refractory blonde/grey hairs. UCSF guidelines at transcare.ucsf.edu/guidelines/hair-removal.
- Pre-vaginoplasty genital/perineal clearance: required for scrotal-skin-inversion and penile-inversion vaginoplasty (prevents intravaginal hair, granulation tissue, infection, stones).
- Salibian 2022 PRS Global Open (PMC9537259): retrospective survey, n=52 (44 full-depth). Electrolysis-only: 24.3 sessions, 48.1 h, $5161 average, pain 6.9, 91.7% needed anaesthesia. Laser-only (eligible patients): 8.1 sessions, 1.9 h, $962, pain 4.4, 33.3% needed anaesthesia. Both reached pre-op clearance (<5 hairs regrowth / 2 mo).
- Rule of thumb: dark hair → laser first-line; blonde/grey/red or mixed → electrolysis. Many patients need a combined path.
- Insurance (US, 2026): WPATH SOC-8 endorses hair removal as medically necessary for gender-affirming surgery. 2024 HHS Section 1557 rule prohibits sex-based denial. Medicaid: ~half of responding states cover; case-by-case in rest. Pre-surgical genital clearance is the most consistently approved indication. California, Oregon, Washington, New York, Massachusetts Medicaid generally cover facial hair removal as gender-affirming; many other states do not.
- Pre-phalloplasty: donor-site (radial-forearm or ALT flap) clearance to prevent neourethral hair stones and infections; 30-80 h over 6-12 months typical.
10. Cost (US, 2024-25)
Per-session list prices; packages 10-20% less.
| Area | Single session | 6-session package |
|---|---|---|
| Upper lip / chin | $60-150 | $300-750 |
| Full face | $200-500 | $1000-2500 |
| Underarms | $100-175 | $500-900 |
| Bikini | $150-300 | $750-1500 |
| Brazilian | $200-600 | $1000-3000 |
| Legs (full) | $400-900 | $2000-4500 |
| Back | $400-900 | $2000-4500 |
| Full body (single session) | $700-900 | $3000-8000 |
- ASPS 2023 national average single session across regions: ~$389.
- Electrolysis comparison: $50-150/hr typical; $120-200/hr NYC/LA/Chicago metro. For large coarse-hair areas electrolysis is far more expensive than laser; for fine/light/grey hair electrolysis is the only option.
11. Home devices (C2/C3)
- Regulatory: FDA-cleared under 510(k) for "permanent hair reduction"; no home device cleared for "removal."
- Types:
- IPL-based: Philips Lumea, Braun Silk Expert Pro 5, Silk'n, Nood Flasher 2.0, Ulike Air 10 (IPL despite "laser" branding), JOVS Venus Pro.
- True diode laser: Tria Beauty Hair Removal Laser 4X — only FDA-cleared home diode laser (~810 nm).
- Efficacy: Alster & Tanzi 2009 (Silk'n SensEpil, n=30) 37-60% reduction at 6 mo. Trelles 2012 (Philips Lumea, n=20-27) 47-60% at 3 mo, regressing after stopping. Mulholland 2009 (Tria 810, n=49) ~60% at 6 mo. Thaysen-Petersen 2012 review: most effects regrow substantially by 12 mo post-protocol.
- Fluence gap: home 3-10 J/cm² vs clinic 15-30+ J/cm². Longer regimens (typically 2×/week × 4-8 weeks induction, then monthly maintenance).
- Safety: safe at label fluences in Fitz I-IV. Main failure mode: Fitz V-VI burns / PIH. Skin-tone sensor interlock on most major devices. Tria 4X labeled Fitz I-IV only. Eye injury risk if flashed near eye without goggles — do not use on tattoos, moles, or inside bony orbit.
12. IPL as its own modality (C1)
- Broad-spectrum flashlamp 500-1200 nm, filter-selectable (commonly 515-755 cutoffs).
- Non-coherent, polychromatic → less chromophore-specific than laser.
- Dorgham 2020 SMC meta-analysis: alex > IPL in skin of color for count reduction; diode / Nd:YAG ≈ IPL.
- Use case: lower cost, larger spot, multi-indication (vascular, pigment). Generally less efficient than dedicated laser per session. 6-10 sessions typical.
Key sources
- Anderson & Parrish 1983 Science — PMID 6836297
- Altshuler & Anderson 2001 TDT concept — PMID 12030874
- Haedersdal 2006 Cochrane — CD004684
- Husain 2022 systematic review — PMID 35634805
- Williams 2023 network meta-analysis — PMID 37493187
- Dorgham 2020 skin-of-color meta-analysis — PMID 31587390
- Waldman / ASDS 2017 isotretinoin consensus — PMID 28498204
- Ross 2002 Nd:YAG PFB — JAAD Aug 2002
- Smith 2009 PFB — PMC2594258
- Salibian 2022 vaginoplasty — PMC9537259
- Moriguchi 2025 paradoxical hypertrichosis — PMC12040530
- Lanigan 2006 adverse effects — PMID 16816888
- Lerner 2017 ocular injury — PMC5843357
- Trelles 2012 Philips Lumea — PMID 22276783
- Alster & Tanzi 2009 Silk'n — PMID 19187179